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Methylenedioxypyrovalerone (MDPV) is a new psychostimulant cathinone acting as a 
selective dopamine transporter blocker. Due to the concomitant consumption of ethanol 
(EtOH) and new psychoactive substances, it is of interest to explore a possible 
pharmacological interaction between MDPV and EtOH. In locomotor activity assays, 
EtOH (1 g/kg i.p.) elicited a reduction in the stimulant effect induced by low doses of 
MDPV (0.1‐0.3 mg/kg, s.c) in rats, jointly with a decrease in  blood and brain MDPV 
concentrations. Experiments in rat liver microsomes showed different effects 
depending on the [MDPV]/[EtOH] relationship, evidencing, at certain concentrations, 
the enhancing effect of EtOH on MDPV metabolism. These suggest that EtOH interacts 
with MDPV at microsomal level, increasing its metabolic rate. The interaction between 
both substances was also supported by results in plasma EtOH concentration, which 
were significantly increased by MDPV, in such a manner that EtOH elimination rate 
was significantly reduced. The possible toxicological impact of this phenomenon 
deserves further investigation. In contrast, the rewarding properties of MDPV were 
unaltered by EtOH. Microdialysis experiments verified that, in the NAcc, both 
substances could also act synergistically, in such a manner that extracellular dopamine 
concentrations are maintained. Finally, if the psychostimulant effect induced by MDPV 
decreased with EtOH, it could favor the boosting and re-dosing in search of the desired 
effects. However, as the rewarding effect of each dose of the substance would not 
decrease, the addictive liability could increase considerably. Moreover, we must warn 
about the increase in EtOH concentrations when consumed concomitantly with MDPV. 


















The popularity of cathinones as recreational drugs has been increasing since they first 
appeared in the illicit drug market. 3,4-Methylenedioxypyrovalerone (MDPV) is a 
synthetic cathinone which shares pharmacodynamics and structural similarities with 
cocaine and MDMA (3,4-methylenedioxymethamphetamine). Some studies have 
demonstrated that MDPV is even more potent than cocaine in blocking the dopamine 
transporter (DAT), as well as in producing locomotor activation (Baumann et al., 2013; 
Cameron et al., 2013). Moreover, MDPV shows rewarding and reinforcing properties 
similar to those of cocaine (Baumann et al., 2013; King et al., 2015).  
Recreational polydrug use is quite common (Pedersen and Skrondal, 1999). New 
psychoactive substances are also commonly combined with many other drugs, 
especially ethanol (EtOH) (Elliott and Evans, 2014). Many studies in rodents indicate 
that EtOH can alter the pharmacological profile of cocaine, and vice versa (Busse et 
al., 2005, 2004; Masur et al., 1989; Sobel and Riley, 1997). A dose-dependent 
attenuation of cocaine-induced hyperlocomotion when EtOH is administered prior to 
cocaine has been described (Dewey et al., 1997). In rats, EtOH-MDMA co-
administration potentiates MDMA-induced hyperlocomotion and rewarding effect  (Ben 
Hamida et al., 2007; Jones et al., 2010). In fact, in animal models, EtOH increases the 
concentrations of MDMA, and its main metabolite, in blood and brain depending on the 
administration regimen (Ben Hamida et al., 2007; Cassel et al., 2007). Thus, when 
investigating possible drug-drug interactions such as MDPV-EtOH, both 
pharmacokinetics and pharmacodynamics issues must be considered. Just a few 
studies have been published on MDPV metabolism in rats and humans (Anizan et al., 
2014b; Meyer et al., 2010; Negreira et al., 2015). In previous findings from our lab, we 
also have demonstrated in rats a correlation between MDPV brain concentrations and 
















The effects of EtOH on the brain are numerous and extremely complex. EtOH 
potentiates GABAergic transmission, but additional mechanisms elicited by EtOH can 
modulate this effect, triggering different consequences in the striatum (STR) and 
Nucleus accumbens (NAcc). Its metabolism involves alcohol-dehydrogenase (ADH) 
and microsomal oxidases (for review see (Cederbaum, 2012)).  
To date, there is no report describing the pharmacokinetics and/or pharmacodynamics 
of MDPV in the presence of EtOH. Therefore, the aim of this study was to assess 
whether EtOH can modify the psychostimulant and/or conditioning effects of MDPV 
when administered concomitantly, as well as MDPV concentrations in blood and rat 
brain. Moreover, it is known that dopamine (DA) and the NAcc play a key function in 
the neural circuitry underlying psychostimulant action and acquisition of reward. 
Therefore, we investigated the effects of MDPV alone and combined with EtOH on the 
concentration of extracellular DA and its main metabolites in NAcc. The surprising 
results we obtained warranted a study aimed at determining the effects of MDPV on 
EtOH pharmacokinetics and pharmacodynamics. 
2. Experimental procedures 
2.1 Subjects and Drugs 
Male Sprague-Dawley rats (Charles River, Spain), weighing 250-300 g were used. All 
animal care and experimental protocols in this study complied with the guidelines of the 
European Community Council Directive (2010/63/EU) and ARRIVE, and were 
approved by the Animal Ethics Committee of the University of Barcelona.  
MDPV and methylone were synthesized in racemic form as HCl salt in our laboratory 
as described previously (López-Arnau et al., 2012; Novellas et al., 2015). DA·HCl, 3,4-
dihydroxyphenylacetic acid (DOPAC), homovanilic acid (HVA), NADPH, as well as 
chemicals for mobile phase and perfusion medium preparations were purchased from 
















male Sprague-Dawley rats were purchased from Life Technologies Europe. Absolute 
EtOH was purchased from Scharlau (Barcelona, Spain) and diluted in saline at a 
concentration that never exceeded 20% (v/v) to avoid tissue irritation. Animals were 
randomly assigned to the following treatment groups: saline+saline saline+EtOH, 
MDPV+saline or MDPV+EtOH, onwards saline, EtOH, MDPV or MDPV+EtOH groups. 
2.2 Locomotor activity 
After being assigned to the different treatment groups (N= 3–5/group) the animals 
received two habituation sessions (48 and 24 h before the experiment) in the activity 
box (LE8811, Panlab, Barcelona, Spain). On the testing day, the animals were injected 
with saline, MDPV (0.1, 0.3, 1 or 3 mg/kg, s.c.), EtOH (1 g/kg, i.p.) or their combination. 
Since EtOH, at certain doses, can impair or enhance locomotion, it was administered at 
doses reported to not affect basal activity (Cassel et al., 2004; Hodge et al., 2004). 
After drug administration, the animals were immediately placed in the activity box and 
horizontal locomotor activity (HLA) was monitored over a 20-min block during 60, 120 
or 360 min. Occlusions of the photo beams (breaks) were recorded (SedaCom32, 
Panlab, Barcelona). Results are expressed as the area under the curve (AUC), which 
was measured as the total changes from baseline at each recording interval. This 
interval was taken from time 0 until hyperlocomotion vanished, that is, until activity was 
not significantly different from that of the saline group. Accordingly, the effect of 0.1 
mg/kg MDPV ended after 60 min, that of 0.3 and 1 mg/kg after 120 min and that of 3 
mg/kg after 360 min. The ANOVAs were thus performed between the values of the four 
groups at the same time chosen for each MDPV dose. 
2.3 Conditioned place preference (CPP) test  
The apparatus was composed of three distinct compartments (two compartments 
















performed in three phases: preconditioning, conditioning and post-conditioning test. 
During the pre-conditioning phase (days 0 and 1), rats were placed in the middle of the 
corridor and had free access and roam among the three compartments of the 
apparatus for 20 min. The mean time spent in each compartment was recorded (Smart 
3.0, Panlab, Barcelona, Spain).  
During the conditioning phase (days 2, 4, 6 and 8), rats (N= 6-10 /group) were treated 
with saline, MDPV (0.3 or 3.0 mg/kg s.c.), EtOH (1 g/kg i.p.) or both, and immediately 
confined into one of the two conditioning compartments for 30 min. We intended to use 
a dose of EtOH that did not produce CPP on its own (Tzschentke, 2007). On days 3, 5, 
7 and 9 animals received saline and were confined to the opposite compartment. The 
animals were exposed to only one pairing per day and treatments were 
counterbalanced.  
The post-conditioning test (day 10) was conducted identically to the pre-conditioning 
phase. A preference score was expressed in seconds and calculated for each animal 
as the difference between the time spent in the drug-paired compartment in the test 
minus the time spent in the same compartment in the pre-conditioning phase.  
2.4 Surgery and microdialysis experiments 
The microdialysis experiments were carried out on awake rats (N= 3-5/group) 
according to the protocol described by Kehr et al. (2011), with some modifications. 
Rats were anesthetized with ketamine (90 mg/kg i.p) plus xylazine (10 mg/kg, i.p.) and 
placed in a stereotaxic frame. After exposure of the skull, a hole for a guide cannula 
and three holes for the anchor screws were drilled. Then, an intracerebral guide 
cannula (AT6.14.iC, Agntho’s, Lidingö, Sweden) was surgically implanted and aimed at 
the NAcc, according to the coordinates: 1.6 mm lateral, 2.2 mm anterior to bregma and 
6.0 mm ventral to the dura surface (Paxinos and Watson, 2007), and fixed to the skull 
















On the evening before an experiment, a microdialysis probe (AT.6.14.2, Agntho’s, 
Lidingö, Sweden; 2 mm membrane length with 15000 Da cut-off) was inserted into the 
guide cannula and perfused overnight with artificial cerebrospinal fluid (aCSF) solution 
(148 mM NaCl, 2.2 mM CaCl2, 0.8 mM MgCl2, 1.2 mM Na2HPO4 and 0.3 mM 
NaH2PO4) at a flow rate of 0.6 µL/min. On the next day, the flow was changed to 1 
µL/min and after a stabilization period of 2 h, the microdialysis samples were collected 
at 20 min intervals in plastic vials filled with 10 µL of an antioxidant mixture (0.1 M 
acetic acid; 0.27 mM Na2EDTA; 0.5 mM ascorbic acid) (Thorré et al., 1997). The first 
three samples were used for estimation of basal levels of DA, DOPAC and HVA. 
Thereafter, saline, MDPV (0.3 or 3.0 mg/kg s.c.), EtOH (1 g/kg i.p.), or both were 
injected to separate groups of rats and the fractions were collected for 120 or 240 min 
and stored at -80oC before analysis. At the end of the experiments, the animals were 
perfused with paraformaldehyde and the brains were removed and examined for 
correct placement of the probe using Cresyl violet staining. Only the data from those 
rats with correct probe placements were included in the study. 
2.5 Liquid Chromatography/Mass Spectrometry determination of DA and 
metabolites in dialysate samples 
An Agilent 1290 Liquid Chromatography (LC) system equipped with an autosampler 
and coupled to AB Sciex QTRAP 6500 mass spectrometer (MS) was used to quantify 
the corresponding monoamine and metabolites. Chromatographic separation was 
achieved on a Discovery HS F5 (150 mm x 4 mm, 3 µm, Sigma-Aldrich, St. Louis, MO, 
USA) pentafluorophenyl column thermostated at 37 oC. The mobile phase was water 
(A) and methanol (B) with 0.1% of HCOOH in both solvents. An increasing linear 
gradient (v/v) of B was used (t(min), %B), as follows, (0, 0), (0.5, 0), (5.90, 30), (6, 
100), (9, 100), (9.10, 0), (10.0, 0) at a constant flow rate (500 µL/min). The flow was 
















enter the mass spectrometer. The microdialysate samples were refrigerated at 4 oC 
and 20 µL were injected, without sample pretreatment, into the LC-MS/MS system. 
Mass spectrometric quantification in positive ion mode was carried out using the 
following transitions: DA (m/z 154 → 137 and 154 → 91) and DOPAC (m/z 123 → 77). 
A negative ion mode was used in the analysis of HVA (m/z 181 → 122). 
Six standards (from 0.1 nM to 10 nM for DA or from 10 nM to 1 µM for metabolites) 
were prepared daily in a solution composed by aCSF/antioxidant mixture (2:1) to obtain 
the calibration curve. The method showed linearity within the concentration range 
studied and the detection limit (signal-to-noise ratio=3) for DA was 0.05 nM and for 
DOPAC and HVA was 1 nM. The accuracy of the assay was 85 – 115% and the intra- 
and inter-assay coefficients of variation were less than 15%. Analyst v1.4.2 software 
was used to calculate the areas of chromatographic peaks. 
2.6 MDPV concentrations in blood and the STR 
Before blood sampling, rats (N= 6-8/group) were implanted with an intravenous (i.v.) 
jugular catheter under isoflurane anesthesia (Caine and Koob, 1993). Blood samples 
(150–200 μL) were collected from awake rats through the catheter at 5, 10, 20, 30, 40, 
60 and 120 min after MDPV injection (0.3 mg/kg, s.c.) alone or in combination with 
EtOH (1 g/kg, i.p.) and transferred to 300 µL tubes with EDTA. According to the method 
previously described (Novellas et al., 2015), 90 μL of plasma was mixed with 10 μL of 
an internal standard (IS) solution (methylone, 200 ng/mL). The mixture was extracted 
by adding 250 μL of methanol. After centrifugation (10,000 × g, 5 min)., 250 μL of 
supernatant were acidified with HCOOH (50%) (Sørensen, 2011). The mixture was 
ultrafiltered and 100 μL of the filtrate were transferred to an autosampler vial to quantify 
MDPV concentrations by LC-MS/MS (Novellas et al., 2015). 
A PE Sciex API3000 triple quadrupole mass spectrometer equipped with an 
















samples. Chromatographic separation was achieved on a Luna C18 (100 × 2.0 mm, 
2.5 μm) column. The mobile phase was water (A) and methanol (B) with 0.1% of 
HCOOH in both solvents. An increasing linear gradient (v/v) of B was used (t (min), 
%B), as follows, (0, 5), (20, 95), (22, 95), (22.5, 5) and (27.5, 5), at a constant flow rate 
(150 μL/min). 5 μL of biological samples were injected into the LC-MS/MS system.  
As there is a direct correlation between brain concentrations and hyperlocomotion 
elicited by MDPV (Novellas et al., 2015), we quantified MDPV in rat STR after its 
administration alone (0.3 and 3 mg/kg s.c.) or with EtOH (1 g/kg i.p.). To minimize the 
number of animals used in this study and according to the data of locomotor activity, 
the MDPV concentrations in STR were measured only at 20 min after drug 
administration. Moreover, a blood sample was also collected and MDPV plasma 
concentrations were quantified as above in order to calculate the brain/blood ratio at 
this time. 
This experiment was carried out as described by Novellas et al., 2015, with minor 
modification. Briefly, rats STR (N= 5/group) were homogenized and centrifuged (1000 
× g, 20 min). The sample plus IS (methylone) was applied to a C8 Sep-Pak® SPE 
cartridges (Waters Corp., Milford, MA, USA). MDPV was eluted with methanol and 
transferred in an auto sampler vial to quantify MDPV concentrations by LC-MS/MS as 
above. 
2.7 Blood EtOH concentration (BEC) 
Blood samples (150-200 μL) from animals (N= 4/group) were collected through vein 
catheters at 5, 10, 20, 30, 40, 60 and 120 min after EtOH injection (1 g/kg i.p.) alone or 
in combination with MDPV (0.3 mg/kg, s.c.). 80 µL of plasma were transferred to 
sample microvials, combined with 20 µL of IS solution (1-propanol, 1 g/L) and placed in 
a water bath at 50ºC for 5 min. Then, 1 mL of the headspace gas was injected with a 
















with a flame ionization detector (FID). EtOH and IS were separated on a capillary 
column (Supelcowax-10®, 30m x 250µm x 0.25µm) using helium as a carrier gas 
(2.0mL/min, split ratio 20:1). The column oven temperature was isothermal at 55ºC and 
the injector and the FID system were selected at 150 and 200ºC, respectively. BECs 
were quantified from linear standard curves in EtOH-free plasma (0.1 – 2 g/L EtOH) 
using the peak area ratios of EtOH to the IS using Agilent Chemstation software. 
2.8 MDPV metabolism in rat liver microsomes 
The evaluation of MDPV metabolism was carried out at 37°C in a shaking bath. 
Preliminary experiments were performed to determine whether MDPV metabolism was 
linear with respect to time and to evaluate the percentage of MDPV metabolized. The 
final incubation mixtures (250 µL) contained MDPV (1 or 10 µM), EtOH (0, 0.1, 1.0, 10 
or 100 mM), rat liver microsomes (0.5 mg protein/mL), and NADPH (1 mM) in 100 mM 
sodium phosphate buffer (pH 7.4). After a 5-min pre-incubation with NADPH, the 
reactions were initiated by the addition of rat liver microsomes and stopped 3 min later 
by the addition of 625 µL ice-cold methanol. A negative control in the absence of 
NADPH was employed to verify the NAPDH-dependent reaction. All the experiments 
were performed in triplicate. To each reaction mixture, 20 µL IS solution (methylone, 10 
µg/mL) was added. The resulting mixture was centrifuged (10,000 g, 5 min). The 
supernatant was filtered (cellulose acetate membrane pore size 0.22 μm), acidified with 
100 µL HCOOH (50%) and centrifuged (12,000 g, 10 min). The supernatants were then 
transferred to HPLC vials, and MDPV concentrations were analyzed by LC-MS/MS as 
previously described. 
2.9 Statistical analysis 
Data were expressed as mean ± standard error of the mean (SEM). Differences 
















of variance (ANOVA) or Student’s t test for independent samples where appropriate. 
Significant differences (p<0.05) were analyzed using the Tukey’s post hoc test for 
multiple comparison measures (InVivoStat software package). In all two-way ANOVA 
analysis, the variable time and the interaction treatment x time were significant. To 
ease reading, the statistics of these variables were not showed. 
3. Results 
3.1 Effects on locomotor activity 
HLA was monitored for 60, 120 or 360 min depending on the MDPV dose (see Table 
1). The AUC analysis of variance demonstrated an overall significant effect of 
treatment variable (AUC0-60min F3,12= 9.73, p<0.001; AUC0-120min F5,16= 30.11, p<0.001; 
AUC0-360min F3,12= 8.33, p<0.01). The post hoc test revealed that MDPV increased the 
locomotor activity at all doses tested compared with the saline group. Moreover, at low 
doses of MDPV (0.1 and 0.3 mg/kg) co-administration of EtOH induced a significant 
decrease (p<0.01) in HLA compared with MDPV alone (See Table 1). Nevertheless, at 
higher doses of MDPV (1 and 3 mg/kg) co-administration of EtOH did not produce any 
change.  
Figure 1 shows the time course of the effects on locomotor activity elicited by EtOH 
and MDPV (0.3 mg/kg Fig. 1A, 3 mg/kg Fig. 1B). At the dose of 0.3 mg/kg, the post hoc 
test confirmed statistical significance between 0.3 mg/kg MDPV and 0.3 mg/kg 
MDPV+EtOH group, suggesting a blockade of the psychostimulant effect elicited by 
MDPV. However, no effects of EtOH on the hyperlocomotion induced by 3 mg/kg 
MDPV were found at any time point. 
3.2 Effect of EtOH on the place conditioning induced by MDPV 
On the test day (day 10, post-conditioning), results revealed a significant effect of 
















preference after being conditioned with both doses. The concomitant administration of 
EtOH did not modify the rewarding effect induced by MDPV. Moreover, as we 
expected, EtOH did not exert any effect on preference score by itself (Fig. 2).  
 
3.3 Effects of MDPV alone or with EtOH on DA, DOPAC and HVA concentrations 
in the NAcc 
Figure 3 shows the time course of the extracellular concentrations of DA in the NAcc of 
animals after an acute administration of MDPV 0.3 mg/kg (panel A) or 3 mg/kg (panel 
B), MDPV+EtOH, EtOH or saline. Two-way ANOVA revealed a significant effect of the 
treatment variable (panel A: F3,11= 8.210, p<0.01; panel B: F3,10= 14.58, p<0.001). 
However, the post-hoc analysis did not show any difference in DA concentrations 
between MDPV and MDPV+EtOH at any time point or MDPV dose tested. 
Administration of MDPV (0.3 and 3 mg/kg) caused a rapid increase in extracellular 
concentrations of DA, reaching changes in peak concentrations of 382.4±74.1% (Fig. 
3A, p<0.001) and 1477.1±524.9% (Fig. 3B, p<0.001) compared to saline, at 20 and 40 
min, respectively. Moreover, we observed a slight increase, although no significant, of 
about 50% in the extracellular concentrations of DA after EtOH (1 g/kg) administration.  
The overall effects of saline, EtOH, MDPV and MDPV+EtOH on the DA concentrations, 
expressed as relative AUC values, are depicted in Figures 4A and 5A. MDPV (0.3 and 
3 mg/kg) caused an increase in total DA of 150.0±35.1% (p<0.01) and 891.1±218.7% 
(p<0.01), respectively, that was unchanged when EtOH was administered 
concomitantly. 
The same samples were also analyzed for the quantification of DOPAC and HVA 
concentrations. Following MDPV administration, the DOPAC and HVA concentrations 
















decline was dampened by EtOH co-administration. In a similar way, when the high 
dose of MDPV was used, a significant reduction in the DOPAC concentrations of 
23.1±6.2% was found (Fig. 5B) without being significantly modifed by EtOH. In 
addition, HVA concentrations remained unchanged (Fig. 5C). 
 
3.4 Effect of EtOH on MDPV concentrations in blood and rat STR 
We measured the plasma concentrations of MDPV over time after s.c. administration of 
0.3 mg/kg alone or in combination with EtOH i.p. There was a significant reduction of 
MDPV concentrations during the first 20 min when combined with EtOH. As shown in 
Figure 6, the statistical test revealed a significant effect of the treatment variable (F1,14 
= 5.969, p<0.05). Moreover, the AUC5

120 analysis also showed a significant decrease 
in the total amount of MDPV (Fig. 6 inset). 
20 min after the MDPV (0.3 mg/kg) injection, the results in STR corroborated the 
decrease in MDPV plasma concentrations described above, (MDPV 0.3 mg/kg= 
133.6±8.5 ng MDPV/g tissue; MDPV 0.3 mg/kg + EtOH 1 g/kg= 77.4±10.4 ng MDPV/g 
tissue (t=4.189, p<0.05)). The assessed brain/blood ratio at 20 min was 2.2 ± 0. 5 after 
MDPV administration and also 2.2 ± 0.5 after MDPV+EtOH. 
Because the combination of EtOH with MDPV 3 mg/kg did not modify MDPV 
hyperlocomotion, we tested the blood and brain concentrations of this combination only 
at the time point of 20 min (maximal psychostimulant effect and maximal striatal 
concentrations; Novellas et al., 2015). Concerning plasma concentrations, no 
significant changes were observed between both groups (MDPV 3 mg/kg= 446.0 ±39.5 
ng/ml; MDPV 3 mg/kg + EtOH 1 g/kg= 385.8 ±25.4 ng/ml; n.s.). As expected, the 
combination with EtOH also resulted in no different striatal concentrations (MDPV: 
















3.5 MDPV metabolism in rat liver microsomes in the presence of EtOH   
The metabolic rate of MDPV was determined using rat liver microsomes. The amount 
of MDPV decreased linearly in a time-dependent manner and at a very high velocity 
(63% of substrate metabolized at 15 minutes). MDPV metabolism was NADPH- and 
microsome-dependent. In order to avoid substrate depletion, the experiments were 
performed with an incubation time of 3 min (25% of MDPV metabolized). The amount 
of MDPV metabolized at 3 min of incubation is expressed as 100% of metabolic rate. 
The effects of increasing amounts of EtOH on MDPV metabolism were then assessed 
(Fig. 7).  
When MDPV was assayed at high concentration (10 µM) (Fig. 7A), EtOH inhibited the 
MDPV metabolism in a concentration-dependent manner (F4,10= 40.56; p<0.001). 
Nevertheless, when using a lower MDPV concentration (1 µM), we demonstrated a 
biphasic effect of EtOH on microsomal activity (F4,10= 29.96; p<0.001) (Fig. 7B). EtOH 1 
mM increased MDPV microsomal metabolism (p<0.01), but at high concentrations (100 
mM) an inhibition of the microsomal activity was found. Consequently, the enhanced 
MDPV metabolism induced by EtOH was evidenced only when combining MDPV and 
EtOH at concentrations of 1 µM and 1 mM, respectively. In these conditions, the 
metabolic rate of MDPV was increased from 100% to 145%.  
3.6 Effect of MDPV on BECs 
We measured the BECs over time after i.p. administration of EtOH alone or in 
combination with MDPV (0.3 mg/kg, s.c.) (Fig 8). After comparing both BEC curves 
versus time, a significant effect of treatment (F1,6=13.97; p<0.001) was observed. BECs 
were significantly higher during 60 min (p<0.01) post-administration in rats given 0.3 
mg/kg MDPV compared to those given 1 g/kg EtOH alone. Furthermore, the AUC 
analysis also supported these differences (Fig. 8 inset; t=3.833, p<0.01). Additionally, 
















allowing us to calculate the corresponding half-life values. MDPV increased the EtOH 
half-life from 23.0±2.4 min to 64.7±9.4 min (t=4.315; p<0.01). 
4. Discussion 
In the present study we have described a pharmacokinetic interaction between MDPV 
and EtOH, substances often consumed concurrently (Elliott and Evans, 2014), that 
could have a significant toxicological impact. The initial approach of this work was to 
assess the effect of EtOH on MDPV-induced changes in behavioral parameters for 
psychostimulant and conditioning properties. The chosen EtOH dose (1 g/kg, i.p.) 
yielded a BEC in the range of that observed after moderate alcohol drinking (Eckardt et 
al., 1998). Our initial finding was of great interest, as EtOH significantly reduced 
locomotor activity counts (70% and 65%) induced by low subcutaneous doses of 
MDPV (0.1 and 0.3 mg/kg, respectively). Being obtained the previous results on 
locomotor activity, our study was mainly focused on two different s.c. doses of MDPV, 
0.3 and 3 mg/kg, which are equivalent to a 3 and 30 mg dose for a 60 kg person 
(Reagan-Shaw et al., 2008), respectively. Tentative estimations pointed towards 
threshold levels around 1-5 mg to “strong” effects between 10-25 mg 
(www.erowid.org). Interestingly, our subsequent experiments using the dose of 3 mg/kg 
MDPV showed that the locomotor effects of this higher dose were not significantly 
affected by EtOH. 
Next, we assayed the effects of EtOH on the rewarding effects (CPP) induced by two 
different doses of MDPV (0.3 and 3 mg/kg). Both MDPV doses produced CPP, with a 
higher significance degree for the dose of 3 mg/kg, but not significantly different with 
respect to the dose of 0.3 mg/kg which showed an important SEM. This probably 
denotes an effect bordering on significance. By contrast, the result of the dose of 3 
mg/kg is more robust and supports a high rewarding effect of this drug at this dose. In 
















three-fold higher after the dose of 3 mg/kg. This points to a dose-response relationship 
in the rewarding effect regardless the lack of significance between doses on CPP. 
Accordingly, other authors (i.e. King et al., 2015) reported that MDPV not always shows 
a clear dose-response effect in the CPP paradigm.    
Conversely to the effect of EtOH on MDPV-induced hyperlocomotion, the rewarding 
properties of MDPV were unaffected by EtOH. If the psychostimulant effect of the 
cathinone decreased with alcohol, it could favor the boosting and re-dosing in search of 
the lost effects. These are typical behaviors followed by consumers of such substances 
(Ross et al., 2012). However, as the reinforcing effect of each dose of the substance 
would not decrease, the addictive liability could increase. 
In an attempt to shed a light on the potential underlying mechanisms for this 
phenomenon, MDPV concentrations were determined both in plasma and STR after a 
single administration of MDPV alone or in combination with EtOH. It is known that 
MDPV crosses the blood brain barrier (BBB) through passive diffusion and active 
transport. This last feature is a differential trait of this compound with respect to other 
synthetic cathinones (Simmler et al., 2013). Thus, we initially hypothesized that EtOH 
could be disrupting the active transport of MDPV through the BBB. In agreement with 
the registered psychostimulant effect, the results revealed a significant reduction (of 
around 50%) in MDPV concentrations in both blood and brain when the cathinone, only 
at the lowest dose tested (0.3 mg/kg, s.c.), was combined with EtOH. Consequently, no 
blood/brain ratio disruption was observed.  
With these results, taking into account the reported extensive metabolism of MDPV 
(Anizan et al., 2014a, 2014b; Meyer et al., 2010; Negreira et al., 2015; Uralets et al., 
2014), the high liposolubility of this drug and the frequent interactions of EtOH with 
other drugs’ metabolism, the most likely explanation for this effect could be a metabolic 
















to test the possibility of an interaction under some specific concentrations of MDPV and 
EtOH. Interestingly we found two opposite effects, depending on [MDPV]/[EtOH] 
relationship. When MDPV was assayed at a high concentration (10 µM), EtOH inhibited 
the MDPV metabolism in a dose-dependent manner. When using a lower MDPV 
concentration (1 µM), we demonstrated a biphasic effect of EtOH. The enhancing effect 
of EtOH on MDPV metabolism was mainly evidenced when combining MDPV 1 µM 
and EtOH 1 mM.  
Therefore, the stimulation of MDPV metabolism induced by EtOH is a reasonable 
explanation for the decrease in MDPV concentrations observed in vivo after 
concomitant administration of EtOH and low doses of MDPV. In fact, a similar 
interaction on microsomal metabolism had already been described for other 
substances. Linnoila et al. (1990) studied plasma concentrations of adinazolam and 
EtOH when administered jointly. They observed higher BEC when administering 
adinazolam after EtOH, while concentrations of the adinazolam main metabolite were 
higher. Moreover, Hellum and Nilsen, (2007) studied the effect of EtOH on the CYP2D6 
mediated metabolism of dextromethorphan. They clearly demonstrated a biphasic 
effect of EtOH on CYP2D6. EtOH, at concentrations from 0.5% to 1.1%, increased 
CYP2D6 activity as compared to control. For EtOH concentrations exceeding 1.5%, a 
linear inhibition of the CYP2D6 activity was found.  
The main enzymes responsible for the transformation from MDPV into its metabolites, 
in rats, are CYP2D1 (rat orthologue of human CYP2D6), CYP2C19 and CYP1A2 
(Meyer et al., 2010; Negreira et al., 2015). CYP2C19 could be inhibited by low 
concentrations of EtOH (Busby et al., 1999). Therefore, CYP2D1 seems to be the main 
candidate to show a stimulant effect of EtOH over MDPV metabolism. However, this 
aspect deserves further investigation and requires extending the study also to the 
















Given the effect of EtOH on locomotor activity, as well as on MDPV concentrations, it 
proved interesting to look for an explanation to the fact that MDPV conditioning 
properties were not affected by the combination. For this purpose, microdialysis 
experiments were performed and changes in DA, DOPAC and HVA in NAcc were 
assessed. We found that MDPV produces a rapid dose-dependent elevation of 
extracellular DA, as expected (Schindler et al., 2015). As previously described for a 
DAT blocker (Kalivas and Duffy, 1990; Müller et al., 2004; Shimada et al., 1996), in 
parallel with an increase in DA concentration, a slight decrease in DA metabolites was 
found. This occurs because DA metabolism by MAO takes place inside the nerve 
terminal. The resulting DOPAC is actively transported to the synaptic cleft (Miyamoto et 
al., 1991). As MDPV inhibits DAT, DA metabolism is reduced. Similar effects were 
observed at 3 mg/kg, except for HVA, which can be explained by the high extracellular 
DA concentrations reached (1500%, Fig. 3B) allowing metabolism by COMT, which is 
localized in the plasma membrane (Trendelenburg, 1990). 
Similarly, EtOH-treated animals showed a slight increase, although no significant, in 
DA concentrations. It is known that EtOH modulates the function of GABAA receptors, 
reducing DA release. In the VTA, however, EtOH decreases rather than increases 
GABAergic neurotransmission (Stobbs et al., 2004; Xiao et al., 2007), leading to 
increased mesoaccumbal DA release (Martí-Prats et al., 2015; Melendez et al., 2003; 
Yoshimoto et al., 1992). Thus, while in the NAcc this substance increases the release 
of DA, in the dorsal STR it does just the opposite (Budygin et al., 2001). This is the 
reason why the effect of EtOH on motor activity is more likely to vary depending on the 
different experimental conditions, whereas its reinforcing and rewarding effect are clear 
and reproducible (Acevedo et al., 2013; Cunningham et al., 2002; Durcan and Lister, 
1988; Frye and Breese, 1981; Milton et al., 1995; Morales et al., 2012; Robledo et al., 
















Interestingly, the increase in DA concentrations induced by MDPV was not 
significantly modified by EtOH. In fact, EtOH may increase DA release. Although this 
increase was not statistically significant when administered alone, significant levels 
could be reached when combined with the DA uptake inhibition induced by MDPV. This 
should result in increased extracellular DA levels and potentiation of the effects of 
MDPV. However, the pharmacokinetic interaction with 1 g/kg EtOH observed at 0.3 
mg/kg MDPV produces decreased blood and brain MDPV levels, so the effect of 
MDPV should be lower than expected when combined with EtOH, making a 
potentiation more unlikely. In our experiments, such decreased effect of MDPV appear 
to be compensated by the DA release induced by EtOH which may act synergistically 
with the uptake inhibition. At 3 mg/kg, the increase in DA concentration induced by 
MDPV is so high that probably could mask the enhancing effect of EtOH, which cannot 
be appreciated. 
At that moment, we also wondered if, in addition to MDPV concentrations, those of 
EtOH could be modified when combining both drugs. Interestingly, BEC’s were very 
significantly increased by MDPV, in such a manner that its elimination rate was 
extremely reduced (half-life increased from 23.01 ± 2.35 min to 64.69 ± 9.36, p<0.01). 
For this reason, it is really feasible that the decrease in DA (as a consequence of 
lower amounts of brain MDPV) was compensated by the increase in DA elicited by 
higher EtOH concentrations, yielding similar conditioning effects. Accordingly, 
although synaptic DA concentrations were similar, the amount of DA taken up into the 
terminal (and thus metabolized into DOPAC and HVA) was higher, as expected for a 
milder blockade of DAT, due to lower concentrations of MDPV.  
The effects on locomotor activity must be discussed apart, as it results from increased 
DA not only in NAcc but also in other brain areas where EtOH inhibits DA release, so 
the psychostimulant effect of MDPV can be modified in a different way than the 
















Due to the possible toxicological impact, it would be interesting to study the exact 
mechanism responsible of increased BEC by the presence of MDPV. On one hand, 
Meyer et al. (2012) suggest that ADH has a large impact on the β-keto group reduction 
of cathinones (Meyer et al., 2012). On the other hand, studies carried out in urine of 
MDPV users demonstrate the absence of the metabolic product of this β-keto 
reduction, likely due to both pyrrolidine- ring and methylenedioxy- group of MDPV 
(Uralets et al., 2014). Therefore, MDPV could not act as a substrate of ADH but might 
inhibit ADH activity, impairing ethanol metabolism. However, this hypothesis requires a 
thorough study of the effect of MDPV on ADH. 
Finally, we would like to stress that under certain conditions the combination of MDPV 
plus EtOH reduces the psychostimulant effect of the cathinone, whereas its reinforcing 
effect is maintained. This would lead to repeat or increase drug intake in search of the 
desired stimulation, while the accompanying extra reinforcement could induce higher 
abuse liability. Due to the possible toxicological impact, further research focused on 
finding out the exact mechanism by which MDPV increases EtOH half-life and whether 
this phenomenon takes also place in humans is warranted. Moreover, from the present 
results is mandatory to warn about the risk of EtOH intoxication when this is consumed 
concomitantly with MDPV. 
Conclusions 
In summary, EtOH, at low-moderate doses, seems to trigger a strong decrease in 
overall concentrations of MDPV, when low doses of cathinone are administered, which 
dampens the MDPV-induced hyperlocomotion. This phenomenon could be explained 
by a pharmacokinetic interaction in the metabolic process. Therefore, MDPV and EtOH 
can interact at microsomal level, increasing the metabolic rate of MDPV. The 
interaction between both substances was also supported by results on BEC, which 
















was significantly lowered. In the NAcc, both substances could also act synergistically, 
in such a manner that although brain MPDV concentrations are lower, the synaptic DA 
concentration is maintained high enough by EtOH to elicit a similar reinforcing effect. 
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Legends for figures: 
Figure 1: Time course of locomotor activity induced by saline, EtOH, MDPV or MDPV 
plus EtOH administration. In panel A (MDPV 0.3 mg/kg), two-way ANOVA revealed the 
effect of the treatment variable (F3,11= 24.49, p<0.001). In panel B (MDPV 3 mg/kg), 
two-way ANOVA also denoted the effect of treatment (F3,11= 10.12, p<0.01). Data are 
expressed as the mean ± SEM. */#p<0.05, **/##p<0.01 or ***/###p<0.001 vs. saline 
group at the corresponding time point; &&p<0.01, &&&p<0.001 vs. MDPV+EtOH group 
at the corresponding time point. 
Figure 2: Effect of EtOH on MDPV-induced conditioned place preference. Results are 
expressed as the mean ± SEM. *p<0.05 or ***p<0.001 vs. saline group. 
Figure 3: Effect of saline, EtOH, MDPV alone (0.3 mg/kg, panel A, or 3 mg/kg, panel 
B) or in combination with EtOH on extracellular levels of DA in the NAcc of awake rats. 
The arrow indicates the time of drug or saline administration. Data are mean ± SEM 
and expressed as a percentage of preinjection baseline values (% basal). *p<0.05, 
**p<0.01 or ***p<0.001 MDPV vs. saline group. #p<0.05, ##p<0.01 or ###p<0.001 
MDPV+EtOH vs. saline group. 
Figure 4: Overall effects of saline, EtOH, MDPV alone (0.3 mg/kg) and plus EtOH on 
DA (panel A), DOPAC (panel B) and HVA (panel C) levels in the NAcc of awake rats. 
The columns represents the AUC0-120min values calculated as the differences in relative 
changes (%) in these compounds between the drug- and saline-treated groups. 
*p<0.05, **p<0.01 vs. saline group; &p<0.05 vs. MDPV+EtOH group. 
Figure 5: Overall effects of saline, EtOH, MDPV alone (3 mg/kg) and plus EtOH on DA 
(panel A), DOPAC (panel B) and HVA (panel C) levels in the NAcc of awake rats. The 
columns represents the AUC0-120min values calculated as in Figure 4. *p<0.05, **p<0.01 
















Figure 6: Time-course of MDPV plasma levels after s.c.  administration of MDPV alone 
(0.3 mg/kg) (filled circles) or in combination with EtOH (open circles). Data are 
expressed as the mean ± SEM. *p<0.05, **p<0.01 or ***p<0.001 vs. MDPV+EtOH 
group at the corresponding time point. Inset: Overall effect of EtOH on AUC values of 
MDPV plasma levels. *p<0.05 vs. MDPV group. 
Figure 7: In vitro metabolism of MDPV by rat liver microsomes. MDPV 10 µM (panel A) 
or 1 µM (panel B) was incubated with rat liver microsomes) in the presence of different 
EtOH concentrations. A negative control (Ctrl -) in the absence of NADPH was 
included. The amount of MDPV metabolized at 3 min of incubation is expressed as 
100% of metabolic rate (positive control, Ctrl +) and the rest of results are normalized 
by this value. Data are the mean ± SEM of the percentage of MDPV metabolic rate. 
**p<0.01 or ***p<0.001 vs. Ctrl +. 
Figure 8: Time course of BEC’s after the administration of EtOH alone (filled circles) or 
in combination with MDPV (open circles). Data are expressed as the mean ± SEM. 
**p<0.01 vs. EtOH group at the corresponding time point. Inset: Overall effect of 
















Table 1: Effect of MDPV alone or in combination with EtOH on HLA in rats. Results are 
expressed as mean ± SEM and represent the measurement of the area under the 
curve (AUC).  
*p<0.05, **p<0.01, ***p<0.001 vs.saline. 
#p<0.05, ##p<0.01 vs. the corresponding MDPV group. 
Drug 
 AUC 
0-60 min 0-120 min 0-360 min 
Saline 10565 ± 1809 14359 ± 3233 15485 ± 3164 
EtOH 1g/kg 13433 ± 2228 13827 ± 2300 15085 ± 2239 
MDPV 0.1 mg/kg 30950 ± 5401 
** 
- - 
MDPV 0.1 mg/kg + EtOH 9050 ± 2278 
## 
- - 
MDPV 0.3 mg/kg -
 
88016 ± 10189 
** 
- 
MDPV 0.3 mg/kg + EtOH -
 
30506 ± 6160 
# 
- 
MDPV 1 mg/kg -
 
134596 ± 17712 
*** 
- 
MDPV 1 mg/kg + EtOH - 140915 ± 13917 
***
 - 
MDPV 3 mg/kg -
 
- 202924 ± 38741 
*
 












































































































































































 The effects of a concomitant administration of EtOH and MDPV were 
studied. 
 EtOH reduced the psychostimulant but not the rewarding effect induced 
by MDPV. 
 EtOH produced a reduction in MDPV concentrations in both blood and 
striatum. 
 EtOH half-life increased 3-fold when MDPV was coadministered. 
 In vitro, the effects on MDPV metabolism depended on [MDPV]/[EtOH] 
relationship. 
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